Femoropopliteal

IN.PACT Study | Should We Start Using DCBs More Frequently in Cases of Femoropopliteal Disease?

With the new devices (drug-eluting balloons , drug-eluting stents , and atherotomes) percutaneous treatment is becoming the...

Safety of Atherectomy in Femoropopliteal Disease

Peripheral artery disease hinders patient quality of life extensively. In advanced stages, such as critical lower limbs...

Drug Coated Balloons in Femoropopliteal Territory: Predictors of Failed Patency

Endovascular treatment in femoropopliteal territory has become the strategy of choice over time, with diverse devices; among...

EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory

Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early...

Results of the COMPARE Study After 2 Years: Low Dose vs. High Dose Paclitaxel-Coated Balloons

The development of new devices and techniques has expanded the range of patients who benefit from endovascular...

Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease

Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that...

DISRUPT-PAD III: Followup of IVL Treatment in Femoropopliteal Territory

Femoropopliteal segment calcification can generate complications for both preparation and execution of endovascular therapies for patients with...

Intermittent Claudication: Invasive Treatment Superior to Pharmacological Treatment?

Peripheral vascular disease is strongly associated to cardiovascular events and a negative impact on health status and...